A.Menarini Pharma U.K. S.R.L.

Menarini House, Mercury Park, Wycombe Lane, Wooburn Green, Buckinghamshire, HP10 0HH
Telephone: +44 (0) 1628 856400
Fax: +44 (0) 1628 856402
Medical Information Direct Line: 0800 085 8678
Medical Information e-mail: menarini@medinformation.co.uk
Out of Hours contact: menarini@medinformation.co.uk

Summary of Product Characteristics last updated on the eMC: 23/10/2008
SPC Migard

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 23/10/2008 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   15-Jul-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Update to section 4.8 Undesirable effects

 

  • Adverse reactions table is updated due to migration to MedDRA system organ classification
  • Statement added regarding post-marketing reports of hypersensitivity reactions.

 

Update to section 10 Date of Revision of the text

 

  • Date of revision updated to July 2008
Updated on 11/03/2008 and displayed until 23/10/2008
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   02/2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 2 – Include excipient details for lactose

Section 4.4 - Update warning on prolonged use of painkillers for headaches, add reference to lactose.

Section 4.9 – Update information on overdose

Section 6.1 – Update details for the film coat (Macrogel 3000)

Sections 9 and 10 – Update date of renewal and revision of the text

Updated on 06/09/2005 and displayed until 11/03/2008
Reasons for adding or updating:
  • Removal of Black Triangle
Updated on 13/07/2005 and displayed until 06/09/2005
Reasons for adding or updating:
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 28/09/2004 and displayed until 13/07/2005
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 28/09/2004 and displayed until 28/09/2004
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Pending awaiting re-submission
Updated on 28/09/2004 and displayed until 28/09/2004
Reasons for adding or updating:
  • Change to section 6. 6 - Instruction for Use/Handling
Updated on 28/09/2004 and displayed until 28/09/2004
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
   frovatriptan